Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724242 | PMC |
| http://dx.doi.org/10.1111/all.16391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinico-Dermoscopic Report of Molluscum Dermatitis: A Pearly Puzzle in Focus.
Cureus
December 2024
Dermatology, Venereology and Leprosy, Kauvery Hospital, Chennai, IND.
We report an 18-year-old male who presented with a two-month history of a lesion over his right forearm with a one-week history of sudden increase in size associated with pain. General and systemic examinations were normal. Dermatological examination revealed a single tender, well-defined, pearly white to erythematous, dome-shaped nodule of approximately 6mm x 5mm x 5mm with central umbilication and surrounding erythema.
View Article and Find Full Text PDFFactors associated with quality of life of chronic spontaneous urticaria patients in a Vietnamese population.
PLoS One
January 2025
Department of Dermatology, Hanoi Medical University, Hanoi, Vietnam.
Objective: Chronic spontaneous urticaria (CSU) is a challenging condition that significantly impacts the affected patients. This study aimed to evaluate the quality of life (QoL) among patients with CSU in Vietnam and identify factors associated with QoL.
Methods: A cross-sectional study was conducted at the Vietnam National Dermatology and Venereology Hospital from June 2023 to March 2024.
Consideration of the EXiLE test for predicting anaphylaxis after diclofenac etalhyaluronate administration.
J Immunotoxicol
December 2024
Teikyo University, Tokyo, Japan.
Diclofenac etalhyaluronate, an active pharmaceutical ingredient in JOYCLU (JCL), serves as a joint function improvement agent in knee and hip osteoarthritis patients. However, frequent cases of anaphylaxis induced by JCL administration have been reported. Recent clinical research suggests the potential utility of the basophil activation test (BAT) in predicting JCL-induced anaphylaxis.
View Article and Find Full Text PDF[Allergology : what's new in 2024].
Rev Med Suisse
January 2025
Service d'immunologie et d'allergologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
In recent years, studies have focused on the in vitro diagnosis of immediate drug reactions, with new recommendations concerning the use of the basophil activation test. Air pollution, particularly fine particles with a diameter of less than or equal to 2.5 m (PM2.
View Article and Find Full Text PDFTargeted dual biologic therapy for erythroderma of unknown etiology guided by high-parameter peripheral blood immunophenotyping.
Sci Rep
January 2025
Department of Dermatology, University of Maryland School of Medicine, 419 West Redwood Street, Suite 235, Baltimore, MD, 21201, USA.
Erythroderma is a severe and heterogeneous inflammatory skin condition with little guidance on the approach to management in cases of unknown etiology. To guide therapeutic selection, we sought to create an immunophenotyping platform able to identify aberrant cell populations and cytokines in subtypes of erythroderma. We performed high-parameter flow cytometry on peripheral blood mononuclear cells (PBMCs) and whole blood of a patient with refractory idiopathic erythroderma, erythrodermic patients with Sézary syndrome and pityriasis rubra pilaris, and healthy controls.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!